The percentage of adults prescribed a GLP-1 drug like Wegovy or Zepbound jumped almost sevenfold over the past five years, ...

The percentage of overweight or obese adults prescribed GLP-1s jumped by almost 587% between 2019 and 2024, according to a ...

The new weight-loss option will cut what the plan sponsors pay as well as what the patients pay, Cigna’s PBM Evernorth says.

Cigna has announced a deal to cap client copays on popular GLP-1 weight loss drugs by Eli Lilly and Novo Nordisk at $200 per ...

The agreements cap monthly out-of-pocket costs for Zepbound and Wegovy at $200 and more deeply discount the drugs for ...

Evernorth said that through direct negotiations with Novo Nordisk and Eli Lilly, patients’ monthly copay costs for Wegovy ...

Cigna’s (NYSE:CI) health services arm, Evernorth, has launched a pharmacy benefit program that caps out-of-pocket costs at $200 per month for patients using the weight-loss drugs - Wegovy from Novo ...

Cigna's pharmacy benefits unit Evernorth said the deal will bring prices down for employers and their workers.

Cigna subsidiary Evernorth Health Services will automate prior authorizations for GLP-1 weight-loss drugs under a new program ...

Cigna (NYSE:CI) on Friday announced plans to launch a new specialized GLP-1 pharmacy called ENGUIDE from next month, as the obesity drug class popularized by Novo Nordisk (NVO) and Eli Lilly (NYSE ...

Cigna is doubling ... also link patients to copay assistance programs for which they may be eligible. Evanko noted that one in ten Americans is set to be on a GLP-1 drug, but significant barriers ...

Cigna's first-quarter financial results got ... which allows clients to lock in savings guarantees or to cap GLP-1 spending when covering the medications for weight loss. It also provides clinical ...